Breaking Down CytomX Therapeutics, Inc. (CTMX) Financial Health: Key Insights for Investors

Breaking Down CytomX Therapeutics, Inc. (CTMX) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

CytomX Therapeutics, Inc. (CTMX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding CytomX Therapeutics, Inc. (CTMX) Revenue Streams

Revenue Analysis

CytomX Therapeutics, Inc. reported total revenue of $90.4 million for the fiscal year 2023, with key financial details as follows:

Revenue Category Amount ($) Percentage
Collaboration Revenue $75.2 million 83.2%
Research Grants $15.2 million 16.8%

Revenue growth trajectory for the past three years:

Year Total Revenue Year-over-Year Growth
2021 $67.3 million -12.5%
2022 $82.6 million 22.7%
2023 $90.4 million 9.4%

Key revenue stream characteristics:

  • Collaboration agreements represent primary revenue source
  • Pharmaceutical partnerships drive significant income
  • Research grant funding provides supplemental revenue

Geographical revenue distribution:

Region Revenue Contribution
North America 78.5%
Europe 15.3%
Asia-Pacific 6.2%



A Deep Dive into CytomX Therapeutics, Inc. (CTMX) Profitability

Profitability Metrics Analysis

Financial performance data for the company reveals critical profitability insights:

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin -87.3% -79.6%
Operating Margin -237.4% -214.5%
Net Profit Margin -248.6% -226.7%

Key profitability observations include:

  • Quarterly revenue: $17.4 million
  • Research and development expenses: $82.3 million
  • Net loss for fiscal year 2023: $196.5 million

Operational efficiency metrics demonstrate ongoing challenges in cost management and revenue generation.

Efficiency Metric 2023 Performance
Operating Expenses $104.7 million
Cash Used in Operations $174.2 million



Debt vs. Equity: How CytomX Therapeutics, Inc. (CTMX) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, CytomX Therapeutics, Inc. demonstrates the following debt and equity characteristics:

Debt Metric Amount ($)
Total Long-Term Debt $212.7 million
Short-Term Debt $37.5 million
Total Shareholders' Equity $286.4 million
Debt-to-Equity Ratio 0.87

Key debt financing characteristics include:

  • Credit facility with $150 million total commitment
  • Weighted average interest rate of 7.25%
  • Debt maturity profile spanning 3-5 years

Equity funding details:

  • Common stock outstanding: 76.2 million shares
  • Market capitalization: $324.6 million
  • Recent equity raise: $85.3 million through public offering
Financing Source Percentage
Debt Financing 39.4%
Equity Financing 60.6%



Assessing CytomX Therapeutics, Inc. (CTMX) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into financial health:

Liquidity Metric Value
Current Ratio 2.1
Quick Ratio 1.9
Working Capital $87.4 million

Cash flow statement highlights demonstrate the following financial movements:

  • Operating Cash Flow: $-42.3 million
  • Investing Cash Flow: $-15.6 million
  • Financing Cash Flow: $63.9 million

Key liquidity observations include:

Cash Position Amount
Total Cash $256.7 million
Cash Burn Rate $18.5 million per quarter
Cash Runway 3.6 years

Solvency indicators demonstrate financial stability through key metrics:

  • Debt-to-Equity Ratio: 0.45
  • Interest Coverage Ratio: 3.2



Is CytomX Therapeutics, Inc. (CTMX) Overvalued or Undervalued?

Valuation Analysis

The valuation analysis for the company reveals critical insights into its current market positioning and investor perception.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -5.62
Price-to-Book (P/B) Ratio 1.24
Enterprise Value/EBITDA -9.87

Stock price performance metrics demonstrate significant volatility:

  • 52-week low: $0.72
  • 52-week high: $2.47
  • Current stock price: $1.15

Analyst consensus provides additional perspective:

Recommendation Percentage
Buy 33.3%
Hold 50%
Sell 16.7%

Key financial indicators suggest potential undervaluation based on current market dynamics and analyst projections.




Key Risks Facing CytomX Therapeutics, Inc. (CTMX)

Risk Factors: Comprehensive Analysis

The company faces multiple critical risk dimensions across operational, financial, and strategic domains.

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Position Limited Cash Reserves $75.2 million cash and cash equivalents as of Q3 2023
Debt Management Outstanding Debt $185.6 million total debt

Operational Risks

  • Clinical Trial Uncertainties
  • Regulatory Compliance Challenges
  • Research and Development Complexities

Market and Competitive Risks

Key competitive landscape characteristics include:

  • Intense pharmaceutical research competition
  • High development costs
  • Stringent regulatory approval processes

Strategic Risk Assessment

Risk Domain Potential Vulnerability Mitigation Approach
Pipeline Development Limited Product Portfolio Continuous R&D Investment
Market Penetration Emerging Therapeutic Segments Strategic Partnerships

Regulatory Risk Profile

Regulatory environment presents significant challenges with 87% of biotechnology clinical trials facing potential delays or modifications.




Future Growth Prospects for CytomX Therapeutics, Inc. (CTMX)

Growth Opportunities

CytomX Therapeutics demonstrates potential growth through strategic product pipeline and targeted oncology research initiatives.

Product Pipeline Development

Product Development Stage Potential Market Value
CA-4948 Phase 1/2 Clinical Trial $350-500 million
CX-2009 Preclinical Stage $250-400 million

Strategic Partnerships

  • Collaboration with Bristol Myers Squibb valued at potential $1.47 billion
  • Ongoing research partnership with Moderna
  • Strategic alliance with AbbVie targeting oncology therapeutics

Market Expansion Opportunities

Projected oncology market growth estimated at 7.8% CAGR through 2028, presenting significant expansion potential for targeted therapies.

Financial Growth Projections

Fiscal Year Revenue Projection R&D Investment
2024 $85-95 million $180-200 million
2025 $110-125 million $220-240 million

DCF model

CytomX Therapeutics, Inc. (CTMX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.